Ipca Laboratories Ltd (IPCALAB)
₹1,762.70
Mkt cap
₹44,720 Cr
P/E ratio
37.90
P/B
5.54
Div yield
0.34%
ROE
15.70%
ROCE
17.00%
EPS (TTM)
₹46.51
Book value
₹318
52W range
1,269–1,901
Sector
Healthcare
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−7.26% from high₹1,763
₹1,269+38.94% from low₹1,901
Current
₹1,762.70
Prev close
₹1,762.00
Day
+0.04%
Price performance
1D
+0.04%
1W
−4.13%
1M
+8.92%
3M
+13.29%
6M
+19.13%
1Y
+19.58%
YTD
+25.55%
Financials
FRevenue, profit & margin
P/E ratio
37.9×
IPCALAB is 11% above the sector median of 34.0×
IPCALAB37.9×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,512 | 1,585 | 2,034 | 2,053 | 2,033 | 2,093 | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 | 2,392 | 2,388 | |
| Expenses | 1,331 | 1,278 | 1,673 | 1,722 | 1,711 | 1,700 | 1,913 | 1,782 | 1,818 | 1,892 | 2,012 | 1,859 | 1,905 | |
| Operating Profit | 181 | 308 | 361 | 331 | 322 | 393 | 441 | 463 | 429 | 416 | 545 | 533 | 484 | |
| OPM % | 12% | 19% | 18% | 16% | 16% | 19% | 19% | 21% | 19% | 18% | 21% | 22% | 20% | |
| Other Income | 36 | 45 | -1 | 91 | -118 | 21 | 26 | 20 | -179 | 33 | -30 | 38 | 48 | |
| Interest | 18 | 31 | 44 | 33 | 29 | 24 | 23 | 17 | 22 | 19 | 20 | 18 | 20 | |
| Depreciation | 70 | 69 | 90 | 100 | 98 | 99 | 100 | 98 | 100 | 100 | 103 | 108 | 107 | |
| Profit before tax | 129 | 252 | 225 | 289 | 77 | 290 | 345 | 368 | 128 | 331 | 392 | 446 | 404 | |
| Tax % | 37% | 34% | 39% | 23% | 96% | 31% | 29% | 25% | 49% | 29% | 28% | 18% | 24% | |
| Net Profit | 78 | 164 | 136 | 221 | 1 | 199 | 246 | 276 | 64 | 233 | 281 | 364 | 307 | |
| EPS in Rs | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 11.79 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.02% · closed higher next day 34 of last 58
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Aug '23◦ | 10 Nov '23◦ | 14 Feb '24◦ | 29 May '24◦ | 13 Aug '24◦ | 14 Nov '24◦ | 13 Feb '25◦ | 29 May '25◦ | 11 Aug '25 | 13 Nov '25 | 13 Feb '26 | 29 May '26 |
| Earnings day | +0.69% | +0.35% | −0.20% | −3.45% | −3.42% | +1.96% | −1.81% | −3.07% | −3.61% | −2.90% | +0.85% | −3.05% |
| +1 day | −1.82% | +0.63% | +7.51% | −10.96% | −4.22% | +2.47% | −0.95% | −3.69% | −0.73% | +10.34% | +1.51% | −5.21% |
| +5 days | −1.54% | +2.30% | +6.58% | −10.22% | +0.44% | +1.93% | −3.08% | −6.74% | −0.24% | +7.26% | −1.57% | +4.42% |
| +15 days | −2.65% | +7.21% | +2.84% | −12.18% | +3.39% | −0.14% | −10.99% | −7.86% | −2.51% | +8.48% | +2.02% | +0.85% |
| +30 days | +0.47% | +4.66% | +6.83% | −5.44% | +5.88% | +10.18% | −5.03% | −1.39% | −2.77% | +7.38% | +2.40% | +15.96% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202644.72%Promoter
Promoters44.72%
FIIs10.72%0.09
DIIs37.04%0.09
Public7.19%0.02
Government0.32%
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Ipca Labs. | ₹1,762.70 | 37.94 | 44,720 | 0.34% | 307 | +80.90% | 2,388 | +6.31% | 16.98% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports13
Concall transcripts37
TranscriptJun 2026TranscriptFeb 2026RECFeb 2026TranscriptNov 2025RECNov 2025TranscriptAug 2025TranscriptJun 2025PPTJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024TranscriptJun 2024TranscriptFeb 2024TranscriptNov 2023TranscriptAug 2023TranscriptApr 2023TranscriptFeb 2023TranscriptNov 2022TranscriptAug 2022TranscriptMay 2022TranscriptFeb 2022TranscriptNov 2021
Credit ratings6
Announcements5
Intimation Of Web Link To Non-Email Cases 17 Jul - Ipca Laboratories schedules 76th AGM on 13 August 2026 and shares annual report web-link.Announcement under Regulation 30 (LODR)-Newspaper Publication 15 JulRecord Date For Dividend 14 Jul76Th Annual General Meeting Of Ipca Laboratories Limited To Be Held On Thursday, 13Th August, 2026 14 Jul - 76th AGM on 13 August 2026; Rs 6 final dividend recommended, record date 7 August 2026.Business Responsibility and Sustainability Reporting (BRSR) 14 Jul - Ipca Laboratories filed its BRSR for FY 2025-26 with ESG, workforce, and sustainability disclosures.